A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma

This is a prospective, single-center, phase II trial designed to evaluate the efficacy and safety of SHR-A1904 monotherapy in second-line or later treatment of advanced neuroendocrine carcinoma. The primary endpoint is the objective response rate. Secondary endpoints include progression free survival, overall survival rate, duration of response, disease control Rate and adverse event.

NCT Number	NCT07520357
Lead Sponsor	Beijing GoBroad Hospital
Conditions	Advanced Neuroendocrine Carcinoma
Enrollment	23 participants
Start Date	2026-04-30
Primary Completion	2028-02-28 (estimated)
Study Completion	2029-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-09